Keywords: Apeirn, GlaxoSmithKline, Lung disease, ARDS, Licensing,
Austria’s Apeiron sells rights to early-stage lung disease drug to GlaxoSmithKline for as much as $332 million
Article | 04 February 2010
Privately-held Austrian biotechnology firm Apeiron Biologics AG has entered into an agreement granting UK drugs giant GlaxoSmithKline, granting the latter ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
